RBC
DPLO

Roble Belko & Company’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Roble Belko & Company’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-117
Closed -$2K – 364
2017
Q1 		$2K Hold
117
– – ﹤0.01% 317
2016
Q4 		$1K Buy
+117
New +$2.18K ﹤0.01% 359

Other funds holding DPLO

FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Roble Belko & Company's DPLO Position: Q2 2017 in Review

Roble Belko & Company sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q2 2017, closing a stake of 117 shares — an estimated $2K sold.

Roble Belko & Company first reported a position in DPLO in Q4 2016 and held it in 2 quarters. The position peaked at $2K in Q1 2017. 175 funds tracked by Wall St. Rank hold DPLO as of Q2 2017.

  • Roble Belko & Company reported no remaining DIPLOMAT PHARMACY, INC. position as of Q2 2017 after selling out during the quarter.
  • Roble Belko & Company sold 117 DIPLOMAT PHARMACY, INC. shares in Q2 2017, an estimated $2K.
  • Roble Belko & Company first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2016 and held it in 2 quarters.
  • Roble Belko & Company's DIPLOMAT PHARMACY, INC. position peaked at $2K in Q1 2017.
  • 175 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q2 2017.

Based on Roble Belko & Company's 13F filing for Q2 2017, filed 11 Aug 2017.